Quest for the right Drug
קבזרה 200 מ"ג KEVZARA 200 MG (SARILUMAB)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תת-עורי : S.C
צורת מינון:
תמיסה להזרקה : SOLUTION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Rheumatoid Arthritis Summary of the safety profile The most frequent adverse reactions are neutropenia (14.2%), upper respiratory infections (7.1%), increased ALT (6.8%), urinary tract infections (5.7%), and injection site erythema (5.3%). The most common serious adverse reactions are infections (2.9%) (see section 4.4). Tabulated list of adverse reactions Adverse reactions listed in the table have been reported in controlled clinical studies. The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Table 2: Adverse reactions System Organ Class Frequency Adverse reaction Infections and infestations Common Upper respiratory tract infection Urinary tract infection Nasopharyngitis Oral herpes Uncommon Pneumonia Cellulitis Diverticulitis Blood and lymphatic system Very common Neutropenia disorders Common Thrombocytopenia Leukopenia Metabolism and nutrition Common Hypercholesterolemia disorders Hypertriglyceridemia Gastrointestinal disorders Rare Gastrointestinal perforation Hepatobiliary disorders Common Transaminases increased General disorders and Common Injection site erythema administration site conditions Injection site pruritus Description of selected adverse reactions Infections In the placebo-controlled population, the rates of infections were 84.5, 81.0, and 75.1 events per 100 patient-years, in the 200 mg and 150 mg sarilumab+ DMARDs and placebo + DMARDs groups respectively. The most commonly reported infections (5% to 7% of patients) were upper respiratory tract infections, urinary tract infections, and nasopharyngitis. The rates of serious infections were 4.3, 3.0, and 3.1 events per 100 patient-years, in the 200 mg, 150 mg sarilumab+ DMARDs, and placebo + DMARDs groups, respectively. In the sarilumab+DMARDs long-term safety population, the rates of infections and serious infection were 57.3 and 3.4 events per 100-patient years, respectively. The most frequently observed serious infections included pneumonia and cellulitis. Cases of opportunistic infection have been reported (see section 4.4). The overall rates of infections and serious infections in the sarilumab monotherapy population were consistent with rates in the sarilumab+ DMARDs population. Gastrointestinal perforation Gastrointestinal perforation was reported in patients with and without diverticulitis. Most patients who developed gastrointestinal perforations were taking concomitant nonsteroidal anti-inflammatory medicinal products (NSAIDs), corticosteroids, or methotrexate. The contribution of these concomitant medications relative to sarilumab in the development of gastrointestinal perforations is not known (see section 4.4). Hypersensitivity reactions In the placebo-controlled population, the proportion of patients who discontinued treatment due to hypersensitivity reactions was higher among those treated with sarilumab (0.9% in 200 mg group, 0.5% in 150 mg group) than placebo (0.2%). The rates of discontinuations due to hypersensitivity in the sarilumab+ DMARDs long-term safety population and the sarilumab monotherapy population were consistent with the placebo-controlled population. In the placebo-controlled population, 0.2% of the patients treated with sarilumab 200 mg every two weeks (q2w) + DMARD reported serious adverse reactions of hypersensitivity reactions, and none from sarilumab 150 mg q2w + DMARD group. Injection site reactions In the placebo-controlled population, injection site reactions were reported in 9.5%, 8%, and 1.4% of patients receiving sarilumab 200 mg, 150 mg, and placebo respectively. These injection site reactions (including erythema and pruritus) were mild to moderate in severity for the majority of patients (99.5%, 100%, and 100%, for sarilumab 200 mg, 150 mg, and placebo respectively). Two patients on sarilumab (0.2%) discontinued treatment due to injection site reactions. Laboratory abnormalities To allow for a direct comparison of frequency of laboratory abnormalities between placebo and active treatment, data from weeks 0-12 were used as this was prior to patients being permitted to switch from placebo to sarilumab. Neutrophil count Decreases in neutrophil counts below 1 x 109/L occurred in 6.4% and 3.6% of patients in the 200 mg and 150 mg sarilumab+ DMARDs group, respectively, compared to no patients in the placebo + DMARDs group. Decreases in neutrophil counts below 0.5 x 109/L occurred in 0.8% and 0.6% of patients in the 200 mg and 150 mg sarilumab+ DMARDs groups, respectively. In patients experiencing a decrease in absolute neutrophil count (ANC), modification of treatment regimen such as interruption of sarilumab or reduction in dose resulted in an increase or normalisation of ANC (see section 4.2). Decrease in ANC was not associated with higher incidence of infections, including serious infections. In the sarilumab+ DMARDs long-term safety population and the sarilumab monotherapy population, the observations on neutrophil counts were consistent with those seen in the placebo-controlled population (see section 4.4). Platelet count Decreases in platelet counts below 100 x 103/µL occurred in 1.2% and 0.6% of patients on 200 mg and 150 mg sarilumab+ DMARDs, respectively, compared to no patients on placebo + DMARDs. In the sarilumab+ DMARDs long-term safety population and the sarilumab monotherapy population, the observations on platelet counts were consistent with those seen in the placebo-controlled population. There were no bleeding events associated with decreases in platelet count. Liver enzymes Liver enzyme abnormalities are summarised in Table 3. In patients experiencing liver enzyme elevation, modification of treatment regimen, such as interruption of treatment or reduction in dose, resulted in decrease or normalisation of liver enzymes (see section 4.2). These elevations were not associated with clinically relevant increases in direct bilirubin, nor were they associated with clinical evidence of hepatitis or hepatic insufficiency (see section 4.4). Table 3: Incidence of liver enzyme abnormalities in controlled clinical studies Placebo + Sarilumab Sarilumab Sarilumab DMARD 150 mg + 200 mg + monotherapy any Dose N = 661 DMARD DMARD N = 467 N = 660 N = 661 AST >3 x ULN – 0% 1.2% 1.1% 1.1% 5 x ULN >5 x ULN 0% 0.6% 0.2% 0% ALT >3 x ULN – 0.6% 3.2% 2.4% 1.9% 5 x ULN >5 x ULN 0% 1.1% 0.8% 0.2% Lipids Lipid parameters (LDL, HDL, and triglycerides) were first assessed at 4 weeks following initiation of sarilumab+ DMARDs in the placebo-controlled population. At week 4 the mean LDL increased by 14 mg/dL; mean triglycerides increased by 23 mg/dL; and mean HDL increased by 3 mg/dL. After week 4 no additional increases were observed. There were no meaningful differences between doses. In the sarilumab+ DMARDs long-term safety population and the sarilumab monotherapy population, the observations in lipid parameters were consistent with those seen in the placebo-controlled population. Malignancies In the placebo-controlled population, malignancies occurred at the same rate in patients receiving either sarilumab+ DMARDs or placebo + DMARDs (1.0 events per 100 patient-years). In the sarilumab+ DMARDs long-term safety population and the sarilumab monotherapy population, the rates of malignancies were consistent with the rate observed in the placebo-controlled population (see section 4.4). Polymyalgia Rheumatica Safety has been studied in one Phase 3 study (SAPHYR) in 117 PMR patients of whom 59 received subcutaneous KEVZARA 200 mg [Pharmacodynamic properties (5.1)]. Of these, 45 patients received KEVZARA for at least 24 weeks, 44 patients for at least 40 weeks, and 10 patients for at least 52 weeks. The total patient years duration in the KEVZARA PMR population was 47.37 patient years during the 12-month double blind, placebo-controlled study. The common adverse reactions occurring in ≥5% of patients treated with KEVZARA were neutropenia (15.3%), leukopenia (6.8%), constipation (6.8%), rash pruritic (5.1%), myalgia (6.8%), fatigue (5.1%), and injection site pruritus (5.1%). Serious adverse reactions of neutropenia occurred in 2 patients (3.4%) in the KEVZARA group compared to none in the placebo group. In both cases of neutropenia, the participants had a neutrophil count less than 500 per mm3 without any infections and resolved following permanent discontinuation of study drug. The most common adverse reactions that resulted in permanent discontinuation of therapy with KEVZARA were neutropenia in 3 patients (5.1%) and infection in 3 separate patients (5.1%), including COVID-19 (n=1), intervertebral discitis (n=1), and pneumonia (n=1). Overall Infections In SAPHYR, the proportion of patients with infections was lower in the KEVZARA group (37.3%) compared to the placebo group (50.0%). Two patients (3.2%) in the KEVZARA group and 1 patient (1.7%) in the placebo group had an event of herpes zoster. Serious infections In SAPHYR, the proportion of patients with serious infections was similar in the KEVZARA group (5.1%) compared to the placebo group (5.2%). Injection Site Reactions In SAPHYR, three patients (5.1%) in the KEVZARA group experienced injection site reactions of pruritus which were mild in severity. No patient in the placebo group experienced injection site reactions. Laboratory Abnormalities Decreased neutrophil count In SAPHYR, decreases in neutrophil counts less than 1,000 per mm3 occurred in 12% of the KEVZARA treated group and no patient in the placebo treated group. Decreases in neutrophil counts less than 500 per mm3 occurred in 3.4% of patients in KEVZARA treated group compared to no patient in the placebo treated group. Decreased platelet count In SAPHYR, decreases in platelet counts between 75,000 to 100,000 per mm3 occurred in two patients (3.4%) in the KEVZARA group, compared to no patient in the placebo treated group. These platelet count decreases were transient and not associated with bleeding events. Elevated liver enzymes In SAPHYR, no KEVZARA treated patients had an ALT or AST greater than 3 times the upper limit of normal (ULN). In the placebo treated group, 2 patients had ALT elevations greater than 3 times the ULN. Lipid Abnormalities In SAPHYR, cholesterol levels ≥299.27 mg/dL were observed in 8/58 (13.8%) patients in the KEVZARA group compared to 4/58 (6.9%) patients in the placebo group. Triglycerides ≥407.4 mg/dL were observed in 3/58 (5.2%) patients in the KEVZARA group compared to 1/58 (1.7%) in the placebo group. No significant differences in mean HDL between KEVZARA group and placebo group were observed. At Week 52, mean increase from baseline for LDL and triglycerides levels were observed in the KEVZARA group though both remained within the normal range. Rheumatoid Arthritis and Polymyalgia Rheumatica Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity with sarilumab. In the placebo-controlled population, 4.0%, 5.6%, and 2.0% of RA patients treated with sarilumab 200 mg + DMARDs, sarilumab 150 mg + DMARDs and placebo + DMARDs respectively, exhibited a positive response in the anti-drug antibody (ADA) assay. Positive responses in the neutralising antibody (NAb) assay were detected in 1.0%, 1.6%, and 0.2% of patients on sarilumab 200 mg, sarilumab150 mg, and placebo respectively. In the RA sarilumab monotherapy population, observations were consistent with the sarilumab + DMARDs population. Anti Drug Antibody (ADA) formation may affect pharmacokinetics of sarilumab. No correlation was observed between ADA development and either loss of efficacy or adverse reactions. The detection of an immune response is highly dependent on the sensitivity and specificity of the assays used and testing conditions. For these reasons, comparison of the incidence of antibodies to sarilumab with the incidence of antibodies to other products may be misleading. In the PMR population, 1 patient (1.8%) in the KEVZARA 200 mg + 14-week corticosteroid taper group exhibited an ADA response. None of the patients in the placebo +52-week corticosteroid taper group exhibited an ADA response. Neutralizing antibodies were detected in the PMR patient with ADA response on KEVZARA 200 mg; the patient did not demonstrate a clinical response. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the safety, and/or effectiveness of sarilumab is unknown. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il
פרטי מסגרת הכללה בסל
א. התרופה תינתן לטיפול בארתריטיס ראומטואידית (Rheumatoid arthritis) כאשר התגובה לתכשירים ממשפחת ה-DMARDs איננה מספקת , בכפוף לתנאי פסקה (ב) ב. טיפול בתרופה לחולה העונה על תנאי פסקה (א), יינתן בהתקיים כל אלה: 1. קיימת עדות לדלקת פרקים (RA-Rheumatoid Arthritis) פעילה המתבטאת בשלושה מתוך אלה: א. מחלה דלקתית (כולל כאב ונפיחות) בארבעה פרקים ויותר; ב. שקיעת דם או CRP החורגים מהנורמה באופן משמעותי (בהתאם לגיל החולה); ג. שינויים אופייניים ל-RA בצילומי רנטגן של הפרקים הנגועים; ד. פגיעה תפקודית המוגדרת כהגבלה משמעותית בתפקודו היומיומי של החולה ובפעילותו בעבודה. 2. לאחר מיצוי הטיפול בתרופות השייכות למשפחת ה-NSAIDs ובתרופות השייכות למשפחת ה-DMARDs. לעניין זה יוגדר מיצוי הטיפול כהעדר תגובה קלינית לאחר טיפול קו ראשון בתרופות אנטי דלקתיות ממשפחת ה-NSAIDs וטיפול קו שני ב-3 תרופות לפחות ממשפחת ה-DMARDs שאחת מהן מתוטרקסאט, במשך 3 חודשים רצופים לפחות. 3. הטיפול יינתן באישור רופא מומחה בראומטולוגיה.
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
טיפול ב-Rheumatoid arthritis | ETANERCEPT, INFLIXIMAB, ABATACEPT, TOCILIZUMAB, TOFACITINIB, CERTOLIZUMAB PEGOL, SARILUMAB |
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
11/01/2018
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף
עלון מידע לצרכן
15.11.18 - עלון לצרכן אנגלית 15.11.18 - עלון לצרכן עברית 04.08.22 - עלון לצרכן עברית 15.11.18 - עלון לצרכן ערבית 07.10.18 - עלון לצרכן 04.08.22 - עלון לצרכן 02.06.22 - עלון לצרכן אנגלית 02.06.22 - עלון לצרכן עברית 02.06.22 - עלון לצרכן ערבית 13.12.22 - עלון לצרכן אנגלית 13.12.22 - עלון לצרכן עברית 13.12.22 - עלון לצרכן ערבית 09.04.24 - עלון לצרכן עברית 07.11.24 - עלון לצרכן אנגלית 07.11.24 - עלון לצרכן עברית 07.11.24 - עלון לצרכן ערבית 16.08.20 - החמרה לעלון 26.01.21 - החמרה לעלון 09.01.22 - החמרה לעלון 04.08.22 - החמרה לעלוןלתרופה במאגר משרד הבריאות
קבזרה 200 מ"ג